other material
confidence high
sentiment positive
materiality 0.75
Iovance raises FY2026 revenue guidance to $410M–$420M, ~15% above prior range at midpoint
IOVANCE BIOTHERAPEUTICS, INC.
- FY2026 revenue guidance raised to $410M–$420M; midpoint is $55M (~15%) above prior $350M–$370M range.
- 2Q26 revenue exceeded guidance by more than 10%; ~$304M cash as of June 30, 2026 supports runway into 2H28.
- ~100 authorized treatment centers as of Oct 5, 2026; ~2,000 patients treated with commercial and clinical Iovance TIL products.
- 5-year Amtagvi data: 31.4% ORR, 19.7% OS, mDOR 36.5 months; real-world ORR ~44% and 52% in patients with ≤2 prior lines.
- TILVANCE-301 Phase 3 frontline melanoma trial (N=670, 80+ sites) enrolls on track; IOV-LUN-202 NSCLC showed 25.6% ORR.